The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
Open accessAbstract
This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it produces four times higher worldwide pneumonia mortality than that by agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers, the lowest dose; male smokers, the highest dose). Poor metabolizer status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity, or inflammation with C-reactive protein (CRP) elevations. The Asian population (Pakistan to Japan) or the Americas’ original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/mL. In the US, daily doses of 300–600 mg/day are recommended. Slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia). This guideline defines six personalized titration schedules for inpatients: 1) ancestry from Asia or the original people from the Americas with lower metabolism (obesity or valproate) needing minimum therapeutic dosages of 75–150 mg/day, 2) ancestry from Asia or the original people from the Americas with average metabolism needing 175–300 mg/day, 3) European/Western Asian ancestry with lower metabolism (obesity or valproate) needing 100–200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250–400 mg/day, 5) in the US with ancestries other than from Asia or the original people from the Americas with lower clozapine metabolism (obesity or valproate) needing 150–300 mg/day, and 6) in the US with ancestries other than from Asia or the original people from the Americas with average clozapine metabolism needing 300–600 mg/day. Baseline and weekly CRP monitoring for at least four weeks is required to identify any inflammation, including inflammation secondary to clozapine rapid titration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Self-citationHuhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Self-citationMeltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Hjorthøj, C., Stürup, A. E., McGrath, J. J., & Nordentoft, M. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30078-0 · Cited by 1,304
Howes, O. D., McCutcheon, R., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M. A. P., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,132
Self-citationThe Maudsley Prescribing Guidelines in Psychiatry
Taylor, D. M., Barnes, T. R. E., & Young, A. H. (2021) · Wiley eBooks · doi:10.1002/9781119870203 · Cited by 988
Tracing the peopling of the world through genomics
Nielsen, R., Akey, J. M., Jakobsson, M., Pritchard, J. K., Tishkoff, S., & Willerslev, E. (2017) · Nature · doi:10.1038/nature21347 · Cited by 728
Clozapine: A Novel Antipsychotic Agent
Oates, J. A., Wood, A. J. J., Baldessarini, R. J., & Frankenburg, F. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241107 · Cited by 687
Siskind, D., McCartney, L., Goldschlager, R., & Kisely, S. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.177261 · Cited by 601
Self-citationZhou, Y., Ingelman‐Sundberg, M., & Lauschke, V. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.690 · Cited by 583
Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998-2005
Moore, T. J. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.16.1752 · Cited by 462
Taipale, H., Tanskanen, A., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tiihonen, J. (2020) · World Psychiatry · doi:10.1002/wps.20699 · Cited by 415
Self-citationMasuda, T., Misawa, F., Takase, M., Kane, J. M., & Correll, C. U. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1702 · Cited by 319
Self-citationInternational trends in clozapine use: a study in 17 countries
Bachmann, C. J., Aagaard, L., Bernardo, M., Brandt, L., Cartabia, M., Clavenna, A., Coma Fusté, A., Furu, K., Garuoliené, K., Hoffmann, F., et al. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12742 · Cited by 314 · cited 1×
“Many clinicians are reluctant to use clozapine in patients with TRS due to systemic barriers and in part because of its toxicity, leading to its underuse in many countries [17].”
BackgroundThe prevalence of psychosis in epilepsy; a systematic review and meta-analysis
Clancy, M. J., Clarke, M. C., Connor, D. J., Cannon, M., & Cotter, D. R. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-75 · Cited by 308
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
Bertilsson, L., Carrillo, J., Dahl, M.-L., LLerena, A., Alm, C., Bondesson, U., Lindström, L., de la Rubia, I. R., Ramos, S., & Benítez, J. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04385.x · Cited by 307
Self-citationSamara, M. T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., & Leucht, S. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2955 · Cited by 300
Jerling, M., Lindström, L., Bondesson, U., & Bertilsson, L. (1994) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199408000-00006 · Cited by 281
Rostami-Hodjegan, A., Amin, A. M., Spencer, E. P., Lennard, M. S., Tucker, G. T., & Flanagan, R. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000106221.36344.4d · Cited by 278
Schulte, P. F. J. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00001 · Cited by 264
Self-citationGhotbi, R., Christensen, M., Roh, H.-K., Ingelman-Sundberg, M., Aklillu, E., & Bertilsson, L. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0288-2 · Cited by 264
Time response of cytochrome P450 1A2 activity on cessation of heavy smoking*1
FABER, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.003 · Cited by 250
Vermeulen, J. M., van Rooijen, G., van de Kerkhof, M. P. J., Sutterland, A. L., Correll, C. U., & de Haan, L. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby052 · Cited by 246
Nielsen, J., Correll, C. U., Manu, P., & Kane, J. M. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08064 · Cited by 232
Self-citationRonaldson, K. J., Fitzgerald, P. B., Taylor, A. J., Topliss, D. J., & McNeil, J. J. (2011) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2011.572852 · Cited by 230
Clozapine: guidelines for clinical management.
Lieberman, J. A., Kane, J. M., & Johns, C. A. (1989) · PubMed · Cited by 226
Self-citationClozapine: Balancing Safety with Superior Antipsychotic Efficacy
Meltzer, H. Y. (2012) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.6.3.5 · Cited by 214
Clozapine‐related seizures: Experience with 5,629 patients
Pacia, S. V., & Devinsky, O. (1994) · Neurology · doi:10.1212/wnl.44.12.2247 · Cited by 199
VanderZwaag, C. J., McGee, M., McEvoy, J. P., Freudenreich, O., Wilson, W. H., & Cooper, T. B. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1579 · Cited by 193
Self-citationClozapine versus other atypical antipsychotics for schizophrenia
Asenjo Lobos, C., Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006633.pub2 · Cited by 188
Worldwide Differences in Regulations of Clozapine Use
Nielsen, J., Young, C., Ifteni, P., Kishimoto, T., Xiang, Y.-T., Schulte, P. F. J., Correll, C. U., & Taylor, D. (2016) · CNS Drugs · doi:10.1007/s40263-016-0311-1 · Cited by 182
Self-citationThe effect of variable cigarette consumption on the interaction with clozapine and olanzapine
Haslemo, T., Eikeseth, P. H., Tanum, L., Molden, E., & Refsum, H. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0209-9 · Cited by 178
Self-citationSex, Race, and Smoking Impact Olanzapine Exposure
Bigos, K. L., Pollock, B. G., Coley, K. C., Miller, D. D., Marder, S. R., Aravagiri, M., Kirshner, M. A., Schneider, L. S., & Bies, R. R. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007310385 · Cited by 177
Self-citationOlesen, O. V., & Línnet, K. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010717 · Cited by 176
Ronaldson, K. J., Fitzgerald, P. B., Taylor, A. J., Topliss, D. J., Wolfe, R., & McNeil, J. J. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.08.018 · Cited by 165
de Leon, J., Ruan, C.-J., Schoretsanitis, G., & De las Cuevas, C. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507638 · Cited by 164
Self-citationTrifirò, G., & Spina, E. (2011) · Current Drug Metabolism · doi:10.2174/138920011796504473 · Cited by 161
Self-citationElevated clozapine levels associated with infection: A systematic review
Clark, S. R., Warren, N., Kim, G., Jankowiak, D., Schubert, K. O., Kisely, S. R., Forrester, T., Baune, B. T., & Siskind, D. J. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.03.045 · Cited by 158
Self-citationBlood Levels to Optimize Antipsychotic Treatment in Clinical Practice
Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19cs13169 · Cited by 148
Self-citationThe impact of clozapine on hospital use: a systematic review and meta-analysis
Land, R., Siskind, D., McArdle, P., Kisely, S., Winckel, K., & Hollingworth, S. A. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12700 · Cited by 141
Self-citationAyala, S., Stubbs, B., Gomez, L., Moore, S., Gaughran, F., Flanagan, R. J., MacCabe, J. H., & Lally, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060863 · Cited by 140
Clinically relevant interactions between newer antidepressants and second-generation antipsychotics
Spina, E., & de León, J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.885504 · Cited by 136
Self-citationClozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists
Kuoppamäki, M., Syvälahti, E. K. G., & Hietala, J. A. (1993) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(93)90126-t · Cited by 127
de León, J., Sanz, E. J., & Cuevas, C. D. L. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz093 · Cited by 126
Self-citationThe Dosing of Atypical Antipsychotics
de León, J., Armstrong, S. C., & Cozza, K. L. (2005) · Psychosomatics · doi:10.1176/appi.psy.46.3.262 · Cited by 124
Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy
Siskind, D. J., Sidhu, A., Cross, J., Chua, Y.-T., Myles, N., Cohen, D., & Kisely, S. R. (2020) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419898760 · Cited by 118
Self-citationSchaber, Stevens, Gaertner, Dietz, K., & Breyer‐Pfaff (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00822.x · Cited by 117
Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility
Dobrinas, M., Cornuz, J., Oneda, B., Serra, M. K., Puhl, M., & Eap, C. B. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.70 · Cited by 117
Self-citationSpina, E., Hiemke, C., & de León, J. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1154043 · Cited by 117
Self-citationImpact of smoking behavior on clozapine blood levels – a systematic review and meta‐analysis
Wagner, E. M., McMahon, L., Falkai, P., Hasan, A., & Siskind, D. J. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13228 · Cited by 117
Self-citationGlucuronidation enzymes, genes and psychiatry
de León, J. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003249 · Cited by 115
Psychopharmacology: Atypical Antipsychotic Dosing: The Effect of Smoking and Caffeine
de León, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.5.491 · Cited by 115
Schoretsanitis, G., Kane, J. M., Ruan, C., Spina, E., Hiemke, C., & de León, J. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1617695 · Cited by 113
Self-citationDíaz, F. J., Santoro, V., Spina, E., Cogollo, M. R., Rivera, T., Botts, S. R., & de León, J. (2008) · Pharmacopsychiatry · doi:10.1055/s-2007-1004591 · Cited by 102
Self-citationPapola, D., Ostuzzi, G., Gastaldon, C., Morgano, G. P., Dragioti, E., Carvalho, A. F., Fusar‐Poli, P., Correll, C. U., Solmi, M., & Barbui, C. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13066 · Cited by 98
Self-citationClozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring
Wiciński, M., & Węclewicz, M. M. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000391 · Cited by 95
Clozapine versus other atypical antipsychotics for schizophrenia
Lobos, C. A., Komossa, K., Rummel‐Kluge, C., Hunger, H., Schmid, F., Schwarz, S., & Leucht, S. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006633 · Cited by 95
de León, J., Rajkumar, A. P., Kaithi, A. R., Schoretsanitis, G., Kane, J. M., Wang, C., Tang, Y., Lin, S., Hong, K. S., Farooq, S., et al. (2019) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_379_19 · Cited by 94
Self-citationReversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients
Chang, W., Lin, S., Lane, H., Wei, F., Hu, W.-H., Lam, Y. F., & Jann, M. W. (1998) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(98)00035-9 · Cited by 92
Self-citationClozapine dose for schizophrenia
Subramanian, S., Vӧllm, B., & Huband, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009555.pub2 · Cited by 87
Facciolà, G., Avenoso, A., Scordo, M. G., Madia, A. G., Ventimiglia, A., Perucca, E., & Spina, E. (1999) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199906000-00017 · Cited by 86
Self-citationRelationship between patient variables and plasma clozapine concentrations: a dosing nomogram
Perry, P. J., Bever‐Stille, K. A., Arndt, S. V., & Combs, M. D. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00531-3 · Cited by 86
Double-Blind Study of Clozapine Dose Response in Chronic Schizophrenia
Simpson, G. M., Josiassen, R. C., Stanilla, J. K., de León, J., Nair, C., Abraham, G., Odom-White, A., & Turner, R. M. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1744 · Cited by 84
Myles, N., Myles, H., Xia, S., Large, M. M. B., Bird, R. J., Galletly, C. A., Kisely, S. R., & Siskind, D. J. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419833166 · Cited by 84
Self-citationVerdoux, H., Quilès, C., & de León, J. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.07.040 · Cited by 83
Self-citationde León, J., Sanz, E. J., Norén, G. N., & Cuevas, C. D. L. (2020) · World Psychiatry · doi:10.1002/wps.20707 · Cited by 82
Self-citationRuan, C., Zang, Y., Wang, C., Cheng, Y.-H., Sun, C., Spina, E., & de León, J. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001018 · Cited by 80
Self-citationSingle Nucleotide Polymorphisms and Haplotypes of CYP1A2 in a Japanese Population
Soyama, A., Saito, Y., Hanioka, N., Maekawa, K., Komamura, K., Kamakura, S., Kitakaze, M., Tomoike, H., Ueno, K., Goto, Y., et al. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.24 · Cited by 79
Zarezadeh, M., Saedisomeolia, A., Shekarabi, M., Khorshidi, M., Emami, M. R., & Müller, D. J. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02421-y · Cited by 78
Self-citationClozapine and all‐cause mortality in treatment‐resistant schizophrenia: a historical cohort study
Cho, J., Hayes, R. D., Jewell, A., Kadra-Scalzo, G., Shetty, H., MacCabe, J. H., & Downs, J. M. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12989 · Cited by 74
Rohde, C., Polcwiartek, C., Kragholm, K., Ebdrup, B. H., Siskind, D., & Nielsen, J. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12827 · Cited by 71
Self-citationIdentification of a novel splice‐site mutation in the CYP1A2 gene
Allorge, D., Chevalier, D., Lo‐Guidice, J., Cauffiez, C., Suard, F., Baumann, P., Eap, C. B., & Broly, F. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01858.x · Cited by 65
Self-citationDíaz, F. J., Josiassen, R. C., & de León, J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000926 · Cited by 61
Rapid clozapine titration in treatment-refractory bipolar disorder
Ifteni, P. I., Correll, C. U., Nielsen, J., et al. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.04.020 · Cited by 56
Self-citationVery High Cytochrome P4501A2 Activity and Nonresponse to Clozapine
Bender, S., & Eap, C. B. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.11.1048 · Cited by 56
Self-citationMoschny, N., Hefner, G., Grohmann, R., Eckermann, G., Maier, H. B., Seifert, J., Heck, J., Francis, F., Bleich, S., Toto, S., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14060514 · Cited by 56
Spina, E., D’Arrigo, C., Santoro, V., Muscatello, M. R. A., Pandolfo, G., Zoccali, R. A., Díaz, F. J., & de León, J. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181c0590e · Cited by 54
Self-citationGuidelines for the use of clozapine in individuals with developmental disabilities
Sabaawi, M., Singh, N. N., & de León, J. (2005) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2005.05.002 · Cited by 53
West, S., Rowbotham, D. S., Xiong, G. L., & Kenedi, C. (2017) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2017.02.004 · Cited by 53
Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients
Wong, J. O.-Y., Leung, S.-P., Mak, T. W. L., et al. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.10.008 · Cited by 52
Clozapine and Gastrointestinal Hypomotility
Cohen, D. (2017) · CNS Drugs · doi:10.1007/s40263-017-0481-5 · Cited by 52
Self-citationUsing therapeutic drug monitoring to personalize clozapine dosing in Asians
de León, J., Schoretsanitis, G., Kane, J. M., & Ruan, C. (2020) · Asia-Pacific Psychiatry · doi:10.1111/appy.12384 · Cited by 52
Self-citationIs there a Future for CYP1A2 Pharmacogenetics in the Optimal Dosing of Clozapine?
Ruan, C., & de León, J. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0015 · Cited by 51
Self-citationClinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents
Spina, E., Barbieri, M. A., Cicala, G., & de León, J. (2020) · Pharmaceuticals · doi:10.3390/ph13120439 · Cited by 51
Self-citationAn update on the complex relationship between clozapine and pneumonia
Schoretsanitis, G., Ruan, C., Rohde, C., Verdoux, H., Cuevas, C. D. L., Spina, E., & de León, J. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1877135 · Cited by 51
Self-citationEffectiveness and safety of rapid clozapine titration in schizophrenia
Ifteni, P. I., Nielsen, J., Burtea, V., Correll, C. U., Kane, J. M., & Manu, P. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12241 · Cited by 49
Self-citationChopra, N., & de León, J. (2015) · The International Journal of Psychiatry in Medicine · doi:10.1177/0091217415621269 · Cited by 48
Self-citationLoi, C., Smith, D. A., & Dalvie, D. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.050278 · Cited by 47
Suhas, S., Kumar, V., Dinakaran, D., Sharma, P., Rao, N. P., Varambally, S. S., Venkatasubramanian, G., Murthy, P., & Gangadhar, B. N. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.05.057 · Cited by 46
Clozapine and mortality: A comparison with other antipsychotics in a nationwide Danish cohort study
van der Zalm, Y. C., Foldager, L., Termorshuizen, F., Sommer, I. E., Nielsen, J., & Selten, J. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13267 · Cited by 45
Self-citationSudden Cardiac Death in Schizophrenia: A Review
Vohra, J. K. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.07.003 · Cited by 44
Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations
de León, J., Tang, Y., Baptista, T., Cohen, D., & Schulte, P. F. J. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12421 · Cited by 41
Self-citationLamotrigine-induced severe cutaneous adverse reaction: Update data from 1999–2014
Wang, X.-Q., lv, B., Wang, H.-F., Zhang, X., Yu, S., Huang, X., Zhang, J., Tian, C.-L., & Lang, S.-Y. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.01.016 · Cited by 40
Clozapine‐induced myocarditis: prescribe safely but do prescribe
Freudenreich, O. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12425 · Cited by 36
Self-citationEuropean Whites May Need Lower Minimum Therapeutic Clozapine Doses Than Those Customarily Proposed
Schoretsanitis, G., Smith, R. L., Molden, E., Solismaa, A., Seppälä, N., Kopeček, M., Švancer, P., Olmos, I. C., Vázquez, M., García, C. I., et al. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001341 · Cited by 33
Self-citationCitrome, L., & Volavka, J. (2021) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000275 · Cited by 32
Self-citationThe significance of sampling time in therapeutic drug monitoring of clozapine
Jakobsen, M. I., Larsen, J. R., Svensson, C. K., Johansen, S. S., Línnet, K., Nielsen, J., & Fink‐Jensen, A. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12673 · Cited by 31
Self-citationDose and safety concerns of clozapine: Worldwide package inserts need revisions
de León, J., Ruan, C., Schoretsanitis, G., & Kane, J. M. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2019.12.009 · Cited by 31
Self-citationZang, Y., Dong, F., Li, A., Wang, C., Guo, G., Wang, Q., Zhang, Y., Zhang, L., de León, J., & Ruan, C. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00673-5 · Cited by 31
Self-citationPharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers
Dobrinas, M., Cornuz, J., & Eap, C. B. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283602e75 · Cited by 29
Self-citationAntipsychotic medication exposure, clozapine, and pneumonia: results from a self‐controlled study
Rohde, C., Siskind, D., Leon, J., & Nielsen, J. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13142 · Cited by 29
Self-citationKuzin, M., Haen, E., Hiemke, C., Bochon, B., Bochon, K., Gründer, G., Paulzen, M., & Schoretsanitis, G. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120985166 · Cited by 24
Self-citationClozapine-induced myocarditis: Separating the wheat from the chaff
Winckel, K., Siskind, D. J., Hollingworth, S., & Wheeler, A. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414554269 · Cited by 23
Self-citationFunctional characterization of 20 allelic variants of CYP1A2
Ito, M., Katono, Y., Oda, A., Hirasawa, N., & Hiratsuka, M. (2015) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2015.03.001 · Cited by 20
Chopra, N., Ruan, C., McCollum, B., Ognibene, J., Shelton, C. I., & de León, J. (2018) · Revista Colombiana de Psiquiatría · doi:10.1016/j.rcp.2018.07.002 · Cited by 8
Self-citation
Cited by
Clozapine-Induced Acute Interstitial Nephritis
Ragg, J., Innes, S., Bannon, F., & Hope, J. (2026) · Journal of clinical psychopharmacology · doi:10.1097/jcp.0000000000002192 · Cited by 2
Metadata
- Authors
- de Leon, J., Schoretsanitis, G., Smith, R. L., Molden, E., Solismaa, A., Seppälä, N., Kopeček, M., Švancer, P., Olmos, I., Ricciardi, C., Iglesias-Garcia, C., Iglesias-Alonso, A., Spina, E., Ruan, C.-J., Wang, C.-Y., Wang, G., Tang, Y.-L., Lin, S.-K., Lane, H.-Y., Kim, Y. S., Kim, S. H., Rajkumar, A. P., González-Esquivel, D. F., Jung-Cook, H., Baptista, T., Rohde, C., Nielsen, J., Verdoux, H., Quiles, C., Sanz, E. J., De Las Cuevas, C., Cohen, D., Schulte, P. F. J., Ertuğrul, A., Anıl Yağcıoğlu, A. E., Chopra, N., McCollum, B., Shelton, C., Cotes, R. O., Kaithi, A. R., Kane, J. M., Farooq, S., Ng, C. H., Bilbily, J., Hiemke, C., López-Jaramillo, C., McGrane, I., Lana, F., Eap, C. B., Arrojo-Romero, M., Rădulescu, F. Ş., Seifritz, E., Every-Palmer, S., Bousman, C. A., Bebawi, E., Bhattacharya, R., Kelly, D. L., Otsuka, Y., Lazary, J., Torres, R., Yecora, A., Motuca, M., Chan, S. K. W., Zolezzi, M., Ouanes, S., De Berardis, D., Grover, S., Procyshyn, R. M., Adebayo, R. A., Kirilochev, O. O., Soloviev, A., Fountoulakis, K. N., Wilkowska, A., Cubała, W. J., Ayub, M., Silva, A., Bonelli, R. M., Villagrán-Moreno, J. M., Crespo-Facorro, B., Temmingh, H., Decloedt, E., Pedro, M. R., Takeuchi, H., Tsukahara, M., Gründer, G., Sagud, M., Celofiga, A., Ignjatovic Ristic, D., Ortiz, B. B., Elkis, H., Pacheco Palha, A. J., LLerena, A., Fernandez-Egea, E., Siskind, D., Weizman, A., Masmoudi, R., Mohd Saffian, S., Leung, J. G., Buckley, P. F., Marder, S. R., Citrome, L., Freudenreich, O., Correll, C. U., & Müller, D. J.
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 2021-12-15
- Volume
- 55
- Issue
- 02
- Pages
- 73-86
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W4200576566
- Cited by
- 275
- References
- 108
- FWCI
- 33.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.